AI is redefining pharmaceutical research and development, accelerating drug discovery, optimising clinical trials, and enhancing precision medicine. Mark Venables explores how AI-driven innovation is reshaping the industry and the challenges companies must navigate to harness its full potential.
The pharmaceutical industry is undergoing a transformation driven by artificial intelligence (AI), with advancements in machine learning and automation expediting drug discovery, clinical trials, and patient care. AI is no longer a speculative tool but a foundational component in modern research and development, offering efficiencies that were previously unattainable.
One process that AI is impacting is drug discovery. Kenza Berkirane, AI Product Leader at Vivanti, explains how AI is accelerating this development by processing vast genomic and clinical datasets. “AI enables faster simulations in target identification by analysing large-scale data to pinpoint potential drug targets,” she says. “By simulating interactions between these targets and various compounds, AI can predict which drugs are most likely to have beneficial effects on specific genomic profiles.
“AlphaFold from DeepMind is a landmark example, revolutionising protein folding analysis by using reinforcement learning. This framework, rooted in game theory, analyses amino acid sequences to predict protein structures, significantly advancing our understanding of biological processes.”
The next frontier in AI-driven drug discovery is further refinement in predictive models, particularly in target validation and toxicity prediction. “Enhancing accuracy in these areas could drastically reduce the time and costs associated with bringing new drugs to market,” Berkirane adds. “Moreover, AI will increasingly enable more personalised approaches to drug development, ensuring treatments are tailored to individual patients rather than broad demographics. AI is also helping researchers explore repurposing existing drugs for new therapeutic applications, a strategy that can dramatically shorten development timelines.”
The role of AI models in pharmaceutical research
The pharmaceutical industry has long relied on computational models, but AI has expanded their capabilities. Different types of AI play specific roles in research and development, from structured data analysis to predictive modelling. “Traditional machine learning models, such as decision trees and predictive analytics, are foundational in pharma, especially given that much of the data is structured and numerical,” Berkirane says. “Deep learning models, like AlphaFold, have become indispensable for complex challenges such as protein folding.”
Reinforcement learning is particularly valuable in decision-making scenarios where multiple variables interact. While large language models (LLMs) have gained attention in other industries, their direct application in pharmaceutical R&D remains limited. “LLMs are useful for patient engagement, summarising regulatory requirements, and clinical documentation,” Berkirane explains. “However, for core R&D, where data is primarily numerical rather than text-based, other AI models are more effective. That said, the potential for LLMs in regulatory compliance and knowledge management is substantial.”
AI also plays a crucial role in identifying effective drug combinations, a traditionally time-consuming process reliant on clinical expertise and historical data. “Machine learning, particularly deep learning, allows us to test numerous drug combinations simultaneously,” Berkirane adds. “AI models analyse interactions between drug targets and disease proteins, making results more interpretable and reliable. The two biggest advantages AI brings to this process are time efficiency and the ability to analyse far more combinations than traditional methods. Additionally, AI-driven simulations are increasingly being used to model how these combinations will interact in real-world scenarios, reducing reliance on lengthy and costly in vitro experiments.”
AI in clinical trials and patient monitoring
AI’s impact extends beyond discovery and into the clinical trial phase, where it is helping pharmaceutical companies optimise patient recruitment and monitoring. Natural language processing (NLP) is already being used to analyse electronic health records (EHRs) to identify eligible patients based on their medical history, diagnoses, and treatment outcomes. In regions with centralised and digitalised healthcare data, such as the NHS in the UK, NLP can scan EHRs to match patients with the most relevant trials, accelerating recruitment timelines.
Beyond recruitment, AI-driven predictive modelling is improving trial efficiency by forecasting patient responses. “AI can simulate trial outcomes based on historical data, reducing the need for extensive preliminary trials,” Berkirane continues. “By analysing past cases, it helps predict how patients with similar backgrounds might respond to treatment, allowing researchers to optimise trial design and resource allocation. AI is also being used to develop adaptive trial designs, where ongoing results inform modifications to study protocols, improving both safety and efficacy.”
Retention is another critical challenge in clinical trials, and AI is proving valuable in maintaining patient engagement. AI-powered tools provide guidance, answer questions, and offer reminders, ensuring participants remain involved throughout the trial process. This is particularly important in trials with complex protocols, where adherence rates can significantly impact the validity of results. AI essentially supplements healthcare professionals by supporting patients throughout their journey, although it cannot replace the empathy and nuanced communication of human care.
The promise of precision medicine
The growing field of precision medicine relies on AI to tailor treatments based on individual patient profiles. Bayesian models are increasingly used to segment patient populations according to age, gender, genetic profile, and medical history. “It’s a similar concept to customer segmentation in e-commerce,” Berkirane says. “Just as companies tailor products to specific customer groups, AI can categorise patients to develop more targeted treatment plans.
“AI-driven precision medicine allows for refined subgroups, leading to genuinely individualised care as data quality and diversity improve. The more granular these subgroups become, the more precisely treatments can be adapted to each patient’s unique needs. AI is also being leveraged in dosage optimisation, where machine learning models assess real-time patient data to recommend the most effective dosing regimens, reducing the risk of side effects.”
Beyond treatment customisation, AI also optimises pharmaceutical marketing and engagement. Predictive analytics allows pharmaceutical companies to generate content efficiently across multiple languages and cultural contexts. AI-powered tools are streamlining the localisation process, ensuring consistent messaging while adapting to regional nuances. Generative AI applications such as image and video generation are also beginning to emerge, though they are still in early development. AI-driven chatbots and virtual assistants are also helping pharmaceutical companies engage with healthcare professionals and patients more efficiently.
Regulatory challenges and the path forward
AI’s rapid integration into pharmaceuticals raises significant regulatory considerations. Balancing innovation with compliance is a challenge for any company looking to leverage AI while adhering to stringent industry standards. “First and foremost, staying informed is essential,” Berkirane says. “Regulations evolve constantly, and companies must proactively monitor changes and build robust processes around data privacy and transparency. Patients are the primary stakeholders, so pharmaceutical companies need to communicate openly about AI’s role in drug development and ensure trust is maintained.
“Internal compliance is just as crucial. Everyone involved, from product managers to developers, must understand regulatory requirements and ethical considerations when handling sensitive health data. Establishing clear protocols ensures alignment across teams, whether dealing with anonymised datasets or identifiable patient information.”
A persistent challenge in AI adoption is data quality. While pharmaceutical companies have vast repositories of data, ensuring these datasets are structured appropriately for AI applications is essential. Many organisations underestimate the work required to clean and organise data before it can be effectively used by AI models. “Companies must assess how data is structured and sometimes even revisit archived datasets to extract valuable insights,” Berkirane adds.
The road ahead
As AI continues to evolve, its impact on pharmaceuticals will only grow. “In research, existing machine learning models will be refined rather than replaced,” Berkirane says. “However, LLMs may enhance explainability by making AI-generated insights more accessible to non-technical stakeholders, streamlining research processes and operational workflows. In marketing, LLMs and generative models will play a more immediate role in automating content creation, improving efficiency, and enabling more precise targeting.”
Transparency will be a critical factor in the responsible deployment of AI. Many large language models function as ‘black boxes,’ meaning their training data and decision-making processes are not always clear. This opacity can lead to biases, particularly if models are predominantly trained on Western datasets. Increasing transparency and developing smaller, more focused AI models could help address these concerns and improve applicability in global markets.
Building public trust in AI will be essential for its success. “Like any disruptive technology, AI generates both excitement and apprehension,” Berkirane concludes. “One of the biggest barriers to adoption is a lack of understanding. Increasing AI literacy across society will help individuals critically evaluate AI’s strengths and limitations. AI should be seen as a tool rather than a decision-maker and fostering transparency will be key to its widespread acceptance in healthcare.”
As AI reshapes the pharmaceutical landscape, companies must navigate the delicate balance between innovation, regulation, and trust. By addressing these challenges head-on, the industry can unlock AI’s full potential to deliver safer, more efficient, and more personalised healthcare solutions.
